Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Pharm Res. 2015 Apr 4;32(9):3029–3043. doi: 10.1007/s11095-015-1684-4

Figure 6.

Figure 6

IHC stains for CD31 expression (red) reveal that vascularity is significantly compromised in both the periphery and core tissue of bumetanide-treated tumors, compared to those treated with the saline control. Not surprisingly, the decrease in CD31 levels coincided with an increase in tumor hypoxia, as evidenced by the increase in pimonidazole staining intensity (green).